Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (AU:ZLD)
ASX:ZLD
ZLD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.92
Previous CloseN/A
Volume190.00
Average Volume (3M)3.82K
Market Cap
$4.40M
Enterprise ValueAU$7.48M
Total Cash (Recent Filing)$38.19K
Total Debt (Recent Filing)$6.30M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding11,897,155
10 Day Avg. Volume8,301
30 Day Avg. Volume3,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue182.99
Enterprise Value/Gross Profit-26.23
Enterprise Value/Ebitda-1.88
Forecast
1Y Price Target
$0.50Price Target Upside44.17% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.34 and its highest was AU$0.92 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.40M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 148 days.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Aug 29, 2025. The company reported -AU$0.104 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.104.
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Undervalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -AU$0.104 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.651%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
Zelira Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$0.50 (44.17% Upside)
$0.50 (44.17% Upside)
Blogger Sentiment
Bearish
AU:ZLD Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.12%
12-Months-Change
Fundamentals
Return on Equity
-263.02%
Trailing 12-Months
Asset Growth
-75.38%
Trailing 12-Months
Company Description
Zelira Therapeutics
Zelira Therapeutics (ZLD) is a global biopharmaceutical company focused on the development and commercialization of clinically validated cannabinoid-based medicines. Operating primarily in the healthcare and biotechnology sectors, Zelira is dedicated to advancing innovative therapies for chronic conditions such as insomnia, autism, and chronic non-cancer pain. The company leverages its proprietary technology platforms and extensive research to deliver high-quality, targeted medical cannabis products to patients worldwide.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―